Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Dose and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease

NCT07758595 is registered in ClinicalTrials.gov with Denali Therapeutics Inc. as lead sponsor.

NCT NCT07758595
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07758595 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Single-Dose and Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL921 in Healthy Participants and Participants With Alzheimer's Disease
Lead sponsor
Denali Therapeutics Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
August 7, 2026
Completion date
April 30, 2030
Enrollment
178 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease, healthy participants